Compare RPRX & DLTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPRX | DLTR |
|---|---|---|
| Founded | 1996 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Department/Specialty Retail Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5B | 20.9B |
| IPO Year | 2020 | 1996 |
| Metric | RPRX | DLTR |
|---|---|---|
| Price | $49.36 | $102.98 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 18 |
| Target Price | $51.40 | ★ $123.35 |
| AVG Volume (30 Days) | 2.5M | ★ 2.9M |
| Earning Date | 05-06-2026 | 06-03-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | N/A | ★ 144.33 |
| EPS | 1.78 | ★ 6.22 |
| Revenue | $2,378,193,000.00 | ★ $19,411,800,000.00 |
| Revenue This Year | $38.63 | $8.48 |
| Revenue Next Year | $4.73 | $5.90 |
| P/E Ratio | $27.85 | ★ $16.37 |
| Revenue Growth | 5.06 | ★ 10.43 |
| 52 Week Low | $31.97 | $78.70 |
| 52 Week High | $50.08 | $142.40 |
| Indicator | RPRX | DLTR |
|---|---|---|
| Relative Strength Index (RSI) | 60.46 | 44.37 |
| Support Level | $35.34 | $103.00 |
| Resistance Level | N/A | $105.99 |
| Average True Range (ATR) | 0.88 | 4.02 |
| MACD | 0.03 | 0.49 |
| Stochastic Oscillator | 77.82 | 42.26 |
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Founded in 1986, Dollar Tree operates almost 9,000 small-box discount stores across the United States and Canada, offering roughly 85% of its merchandise under $2. The chain targets value-conscious suburban and urban shoppers with a mix of consumables (49% of sales), variety (45%), and seasonal goods (6%). In fiscal 2024, Dollar Tree generated over $17 billion in sales, through its multi-price strategy, higher-margin discretionary assortments, and private-label products that account for nearly one-third of sales.